secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-138954
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics reports Q1 loss of $71.2M, VOWST approved, balance sheet strengthened with up to $250M facility
--------------------------------------------------------------------------------

- VOWST (fecal microbiota spores) FDA-approved for recurrent C. difficile; launch expected June 2023.
- Q1 net loss $71.2M vs $56.6M YoY; R&D $44.0M incl. $16M commercial manufacturing; cash $106.5M.
- Entered $250M debt facility with Oaktree; drew $110M (net ~$50M after retiring $53M debt).
- Due $125M milestone from Nestlé Health Science upon VOWST approval; pro-forma cash ~$282M.
- SER-155 Phase 1b Cohort 1 data: favorable tolerability, engraftment, reduced ESKAPE pathogen domination; Cohort 2 data mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523138954/0001193125-23-138954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523138954/d456262d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-138954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer